Research and Markets: Cancer Genomics: Revolutionizing Treatment and Reshaping Markets through Targeted Therapies

[Research and Markets via BizWire]

DUBLIN, Ireland--(BUSINESS WIRE)--April 30, 2004--Research and
Markets (http://www.researchandmarkets.com) has announced the addition
of Cancer Genomics: Revolutionizing Treatment and Reshaping Markets
through Targeted Therapies to their offering.

This Report Reveals What You Need to Know about Critical Issues in
Cancer Genomics:
- An overview of leading pharmacological strategies.
- An outlook for drugs under investigation that target key
pathways.
- A summary and review of drugs in late-stage development.
- Vital business statistics of 22 key players.
- 12 expert commentaries.

Cancer Genomics: Revolutionizing Treatment and Reshaping Markets
through Targeted Therapies provides a realistic assessment of what
genomics technology will bring to the cancer treatment field within
the next decade. Oncology has been impacted more strongly by genomics
and related technologies than any other indication area. Cancer arises
from genetic changes in cells and hence, the availability of tools to
better understand exactly how this occurs is revolutionizing the
field.
Rational cancer drug design, or targeted therapy development, has
become the major focus in this field. Drugs like Genentech/Roche's
Herceptin, and Novartis' Gleevec, illustrate how this new paradigm can
be successful. However, as in many other areas, target validation is
the rate-limiting step in cancer drug discovery and development.
Another major issue is the development of accompanying markers and
assays, both to validate the drug's mechanism of action and to
identify subgroups of patients whose cancers have the biochemical
attributes necessary for a response. It has proven extremely difficult
to find these, and to develop accurate tests. This report evaluates
current efforts to overcome these hurdles, and addresses the following
key focus areas:
- Efforts to single out targets related to the signal transduction
network within cells that are instrumental to growth, proliferation,
cell death, and angiogenesis. Genomics is also being applied to
identify surface tumor antigens that may function as targets for the
development of tumor vaccines and mAb-based products.
- The use of genomics to further elucidate many established
pathways in tumorgenesis and progression, and to identify and describe
many new avenues and specific targets.
- The race to develop cancer agents based on antagonizing growth
factor receptors. Approximately 20 drugs exploiting this mechanism are
in clinical trials. This report is a useful summary to marketing and
licensing departments that need to quickly assess the latest
developments in cancer genomics. It will also enable R&D and
commercial departments to assess competitive developments, and help
guide possible collaborations with specialist companies to complement
in-house activities.
Thought Leaders Interviewed for This Report: Lars Baumbusch, The
Norwegian Radium Hospital Marcia S. Brose, University of Pennsylvania
Cancer Center Sean Buchanan, Structural GenomiX Inc. Barry A. Bunin,
Sertanty C. Cantor, Sequenom Kenneth C. Carter, Avalon Pharmaceuticals
Geoffrey Duyk, Exelixis Riccardo Fodde, Leiden University Medical
Center Alain Jacquemin-Sablon, Laboratoire de Pharmacologie des Agents
Anticancereux Institut Bergonie Annalisa Lorenzato, University of
Torino School of Medicine, Institute for Cancer Research and Treatment
Thorunn Rafnar, Iceland Genomics Corporation Gary Schweikhardt,
Epigenomics AG Liam Seery, EiRx Pharma Karol Sikora, Imperial College,
Hammersmith Hospital Lilian Vakalopoulou, metaGen

Companies Profiled:

Beyond Genomics

Bionomics Ltd.

Compugen

CuraGen

deCODE genetics

diaDexus

EiRx Therapeutics

Epigenomics

Exelixis

Galapagos Genomics

The Genetics Company

Iceland Genomics

Immusol

Incyte Corporation

Maxygen

metaGen Pharmaceuticals

Millennium Pharmaceuticals

Myriad Genetics

PhenoGenomics Corporation

Quark Biotech, Inc.

SEQUENOM

3-Dimensional Pharmaceuticals

For more information visit
http://www.researchandmarkets.com/reports/c1670